Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Change in Accured Expenses (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Change in Accured Expenses for 9 consecutive years, with -$8.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses changed N/A to -$8.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.9 million, a N/A change, with the full-year FY2025 number at $4.9 million, up 1453.87% from a year prior.
  • Change in Accured Expenses was -$8.1 million for Q4 2025 at Soleno Therapeutics, down from $11.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $11.5 million in Q3 2025 to a low of -$8.1 million in Q4 2025.